Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: A mechanistic study

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1455-1469

  Sankar, R ^a   Jain, Subheet Kumar ^a,b  

^a PUNJABI UNIVERSITY   (India)

^b GURU NANAK DEV UNIVERSITY   (India)

Author keywords

Gastroretentive; GI retention study; Mucoadhesive measurement; Pharmacokinetic study; Swelling and mucoadhesive mechanism

Indexed keywords

ACICLOVIR; ALGINIC ACID; CARBOMER; MACROGOL; POLYMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BULK DENSITY; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; FACTORIAL ANALYSIS; GASTRORETENTIVE SUSTAINED RELEASE FORMULATION; IMMEDIATE RELEASE TABLET; IN VITRO STUDY; KINETICS; MATRIX EROSION; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MUCOADHESIVE STRENGTH; NONHUMAN; PHYSICAL PARAMETERS; QUALITY CONTROL; RABBIT; SIMULATION; SUSTAINED RELEASE FORMULATION; SWELLING AND MUCOADHESIVE MECHANISM; SWELLING INDEX; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER GASTROINTESTINAL TRACT;

GASTRORETENTIVE; GI RETENTION STUDY; MUCOADHESIVE MEASUREMENT; PHARMACOKINETIC STUDY; SWELLING AND MUCOADHESIVE MECHANISM;

ACYCLOVIR; ADHESIVENESS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HALF-LIFE; POLYMERS; RABBITS; TABLETS;

EID: 84889604191     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S52890     Document Type: Article

References (48)

1. Hoffman A. Pharmacodynamic aspects of sustained release preparations. Adv Drug Deliv Rev. 1998;33:185-199.
2. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003;90:143-162.
3. Qassim SMA, inventor; Tabuk Pharmaceutical Manufacturing Co, assignee. Pharmaceutical compositions of ciprofloxacin. European patent EP1880722B1. March 17, 2010.
4. Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst. 1999;16:571-639.
5. Dhaliwal S, Jain S, Singh HP, Tiwary AK. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J. 2008;10:322-330.
6. Riner JL, Byford RL, Stratton LG, Hair JA. Influence of density and location on degradation of sustained-release boluses given to cattle. Am J Vet Res. 1982;43(11):2028-2030.
7. Reddy LH, Murthy RS. Floating dosage systems in drug delivery. Crit Rev Ther Drug Carrier Syst. 2002;19(6):553-585.
8. Klausner EA, Eyal S, Lavy E, Friedman M, Hoffman A. Novel levodopa gastroretentive dosage form: in vivo evaluation in dogs. J Control Release. 2003;88(1):117-126.
9. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release. 1999;58(2):195-205.
10. Chen J, Blevins WE, Park H, Park K. Gastric retention properties of superporous hydrogel composites. J Control Release. 2000;64(1-3): 39-51.
11. Akiyama Y, Nagahara N, Nara E, etal. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites. J Pharm Pharmacol. 1998;50(2):159-166.
12. Groning R, Berntgen M. Estimation of the gastric residence time of magnetic dosage forms using the Heidelberg capsule. Pharmazie. 1996;51(5):328-331.
13. Chiou WL, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res. 1998;15(11):1792-1795.
14. Lewis LD, Fowle ASE, Bittiner SB, Bye A, Isaacs PET. Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. Br J Clin Pharmacol. 1986;21(4): 459-462.
15. Gröning R, Berntgen M, Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur J Pharm Biopharm. 1998;46(3):285-291.
16. O'Brien JJ, Campoli-Richards DM. Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989;37(3):233-309.
17. Fuertes I, Miranda A, Millán M, Caraballo I. Estimation of the percolation thersholds in acyclovir hydrophilic matrix tablets. Eur J Pharm Biopharm. 2006;64(3):336-342.
18. Garg R, Gupta GD. Preparation and evaluation of gastroretentive floating tablets of acyclovir. Curr Drug Deliv. 2009;6(5):437-443.
19. Sankar R, Jain SK. Determination of target in vitro drug release profile for extended release formulation of acyclovir through pharmacokinetic simulations. Anti-Infect Agents. 2013;11(2):204-211.
20. United States Pharmacopeia and National Formulary (USP 36-NF 31). Acyclovir tablets. Rockville, MD: The United States Pharmacopeial Convention; 2013:2342-2343.
21. Indian Pharmacopoeia. Uniformity of weight of single dose preparations. Ghaziabad: Indian Pharmacopoeia Commission; 2010;1:192.
22. Indian Pharmacopoeia. Friability of uncoated tablets. Ghaziabad: Indian Pharmacopoeia Commission; 2010;1:193.
23. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Tech. 1996;20:64-74.
24. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-133.
25. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2-3):139-157.
26. Al-Taani BM, Tashtoush BM. Effect of microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium. AAPS PharmSciTech. 2003;4(3):E43.
27. Ravindran VK, Vasa S, Subadhra S, Banji D, Banji O, Rao YM. Comparative study of mucoadhesive polymers carbopol 974P and sodium carboxymethyl cellulose for single unit dosage of imatinib mesylate. Malaysian J Pharm Sci. 2012;10(1):61-77.
28. Badhan AC, Mashru RC, Shah PP, Thakkar AR, Dobaria NB. Development and evaluation of sustained release gastroretentive minimatrices for effective treatment of H. pylori infection. AAPS PharmSciTech. 2009;10(2):459-467.
29. Baskar GV, Narayanan N, Gaikwad R, Abdul S. Formulation and evaluation of gastro-retentive floating multi-particulate system of metoprolol tartarate. Trop J Pharm Res. 2010;9(2):181-186.
30. Nagarwal RC, Ridhurkar DN, Pandit JK. In vitro release kinetics and bioavailability of gastroretentive cinnarizine hydrochloride tablet. AAPS PharmSciTech. 2010;11(1):294-303.
31. Thakar K, Joshi G, Sawant KK. Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies. Drug Dev Ind Pharm. 2013;39(6):880-888.
32. Chary RBR, Vani G, Rao YM. In vitro and in vivo adhesion testing of mucoadhesive testing of mucoadhesive drug delivery systems. Drug Dev Ind Pharm. 1999;25(5):685-690.
33. United States Pharmacopeia and National Formulary (USP 36-NF 31). Acyclovir. Rockville, MD: The United States Pharmacopeial Convention; 2013:2338-2339.
34. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [webpage on the Internet]. ICH Q1C. Stability testing for new dosage forms. 1997. Available from: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. Accessed January 15, 2013.
35. Colorcon. PolyoxTM, Water-Soluble Polymers for Pharmaceutical Applications. Harleysville (PA): BPSI Holdings, LLC; 2009. Available from: http://www.colorcon.com/literature/marketing/mr/Extended%20Release/POLYOX/English/Colorcon_PIB_POLYOX.pdf. Accessed April 12, 2013.
36. Lubrizol. Pharmaceutical Polymers for Oral Solid Dosage Forms. Cleveland (OH): Lubrizol; 2011. Available from: http://www.lubrizol.com/Pharmaceutical-Ingredients/Documents/Brochures/Pharmaceutical-Polymers-for-Oral-Solid-Dosage-Forms.pdf. Accessed April 12, 2013.
37. FMC Corporation. Alginates for Pharmaceutical and Medical Applications: Performance Enhancing Products. Philadelphia (PA): FMC Corporation; 2008. Available from: http://www.fmcbiopolymer.com/Portals/ISP/Content/Docs/Alginates%20for%20Pharmaceutical%20and%20Medical%20Applications.pdf. Accessed April 12, 2013.
38. Chen JL, Cyr GN. Compositions producing adhesion through hydration. In: Manly RS, editor. Adhesion in Biological Systems. New York: Academic Press; 1970:163-181.
39. Duchêne D, Ponchel G. Principle and investigation of the bioadhesion mechanism of solid dosage forms. Biomaterials. 1992;13(10): 709-715.
40. Park H, Robinson JR. Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion. J Control Release. 1985;2:47-57.
41. Shahi S, Sonawane A, Vanamore S, Zadbuke N. Formulation and in vitro characterization of acyclovir floating matrix tablets: a factorial design study. J Applied Pharm Sci. 2013;3(5):65-74.
42. Wells JI, Aulton ME. Preformulation. In: Aulton ME, editor. Pharmaceutics: The Science of Dosage Form Design. London: Churchill Livingstone; 1988:247-248.
43. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [webpage on the Internet]. ICH Q3C(R5). Impurities: guideline for residual solvents; 2011. Available from: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. Accessed April 12, 2013.
44. Gu JM, Robinson JR, Leung SH. Binding of acrylic polymers to mucin/epithelial surfaces: structure-property relationships. Crit Rev Ther Drug Carrier Syst. 1988;5(1):21-67.
45. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011;3(1):89-100.
46. Roldo M, Hornof M, Coliceti P, Bernkop-Schnürch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur J Pharm Biopharm. 2004;57(1): 115-121.
47. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 2006;6(5):501-508.
48. Middleton DL, Leung SS, Robinson JR. Ocular bioadhesive delivery systems. In: Lenaerts V, Gurny R, editors. Bioadhesive Drug Delivery Systems. Boca Raton (FL): CRC Press, Inc; 1990:179-202.